DoD Peer Reviewed Cancer, Impact Award | W81XWH 19 PRCRP IPA

PRCRP Impact Award (FY19) FAQs

What is the DoD PRCRP Impact Award (FY19)?

The Peer Reviewed Cancer Research Program (PRCRP) Impact Award (FY19) is a Department of Defense (DoD) funding opportunity intended to move cancer research beyond early discovery and into studies that can realistically change patient care in the near term. It focuses on hypothesis-driven projects that are already mature, supported by prior findings, and aimed at solving critical scientific or clinical problems in cancer.

What is the main goal of this award mechanism?

The main goal is significant and timely impact. Reviewers are looking for projects that can shift clinical practice, improve patient outcomes, or materially accelerate translation to treatment or prevention strategies, rather than producing incremental advances or adding isolated basic biology findings.

What kinds of research projects are encouraged?

Translational and clinical research are explicitly encouraged, including clinical trials. Competitive projects typically involve well-developed therapeutic strategies, diagnostics, or prevention approaches that are ready for rigorous validation, optimization, or testing in clinically relevant settings.

Does the award support basic research?

The mechanism is described as being positioned beyond the basic research stage. Projects are expected to be on a trajectory toward clinically actionable outcomes and to demonstrate how the work will transform the field toward improved patient care, not simply expand foundational knowledge.

What does “impact” mean in the context of this opportunity?

Impact refers to outcomes that are both meaningful and achievable on a near-term horizon. Proposals are expected to show a clear path to changing clinical practice, improving outcomes, or accelerating translation to prevention or treatment, rather than representing incremental progress.

Are hypothesis-driven projects required?

Yes. The opportunity is aimed at hypothesis-driven projects that are mature and well-supported by prior findings.

How important is preliminary data for an application?

Strong preliminary data are a core requirement. Applications must include preliminary data to demonstrate feasibility and readiness and to justify the proposed next steps toward translational or clinical endpoints.

Can unpublished preliminary data be included?

Yes, but with a restriction: any unpublished data included in the application must come from the Principal Investigator (PI) or members of the project team. This reinforces that the proposal is grounded in the team’s demonstrated capabilities rather than speculation.

Is the Impact Award intended for brand-new research directions?

No. The award emphasizes continuity of research and is meant for established lines of investigation that have progressed beyond basic research and are positioned to deliver near-term clinical or clinically actionable impact.

What kinds of “next milestone” activities does this award seem designed to fund?

Examples described include validating a target in patient samples, refining an intervention, completing key preclinical studies that directly support clinical translation, or conducting clinical testing, including clinical trials where appropriate.

What are FY19 PRCRP Topic Areas, and do projects need to align with them?

The program is designed to support work that would make a major, meaningful difference in at least one of the FY19 PRCRP Topic Areas. The information provided indicates that alignment with at least one topic area is central to the award’s purpose.

Does the program prioritize any particular cancer areas?

Yes. It especially emphasizes cancers or research areas that are under-funded, under-studied, and/or particularly lethal, while still being relevant to the military community.

What does “cross-cutting insights” mean here?

The opportunity encourages research that can reveal common mechanisms or solutions across multiple cancers. This cross-cutting emphasis is intended to help reduce disparities in how cancer research dollars are typically distributed and to generate broader oncology benefits.

Is military relevance required?

Yes. Military relevance is mandatory. Proposed studies must address at least one FY19 PRCRP Military Health Focus Area and must be clearly relevant to active duty Service members, Veterans, and their beneficiaries.

How should an application demonstrate military relevance?

The relevance component needs to be more than a brief statement. The proposal should connect the cancer problem and expected outcomes to the needs of the military health population, such as incidence, exposure risks, survivorship burdens, readiness impacts, or care challenges within the Military Health System and the VA.

Who is the target population for the required military relevance?

The required relevance must tie to active duty Service members, Veterans, and their beneficiaries.

Are clinical trials allowed or encouraged under this award?

Yes. Translational and clinical research are explicitly encouraged, including clinical trials, as long as the proposal makes a strong case that the outcomes are achievable on a near-term horizon.

Which agency and administrative entities issued this funding opportunity?

The opportunity was offered by the Department of Defense, Department of the Army, through USAMRAA (U.S. Army Medical Research Acquisition Activity).

What is the Funding Opportunity Number (FON) for this announcement?

The Funding Opportunity Number is W81XWH-19-PRCRP-IPA.

What is the CFDA number associated with this opportunity?

The CFDA number listed is 12.420.

What funding instruments were used for awards under this opportunity?

The opportunity indicates that funding instruments included grants and cooperative agreements.

Who was eligible to apply?

Eligibility was described as broadly “unrestricted,” meaning many organization types could apply, provided they met any additional requirements in the full announcement.

When was the opportunity posted, and what was the closing date?

It was posted on March 21, 2019, with an original closing date of September 11, 2019.

How many awards were anticipated?

The opportunity anticipated roughly 10 awards.

What was the maximum award amount (award ceiling)?

The summary field shows an “award ceiling” of 0. This typically signals that applicants should rely on the full program announcement for budget limits and expectations rather than the summary field alone.

What types of outcomes would a strong proposal be expected to deliver?

Strong proposals are framed around concrete, high-stakes outcomes with a near-term path to improving cancer care. This can include advancing a mature therapeutic strategy, diagnostic, or prevention approach through rigorous validation or clinically relevant testing, with the goal of improving outcomes for military-connected populations while also advancing the broader oncology field.

What makes this award different from early-stage discovery funding?

This mechanism is designed as a “leapfrog” toward translation: it expects feasibility and readiness supported by strong preliminary data, continuity from an established research line, and a credible plan to reach clinical or clinically actionable endpoints in the near term.